Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767904 | 0.87 | CXCR4 (0.62) | CXCR4TSHRKMT2A | |
| SCHEMBL12507726 | 0.86 | CXCR4 (0.52) | CXCR4 | |
| SCHEMBL1637878 | 0.82 | CXCR4 (0.67) | CXCR4DRD4MEN1KMT2AMAOB | |
| SCHEMBL1206161 | 0.81 | CXCR4 (1.00) | CXCR4TSHRDRD4MEN1KMT2A | |
| SCHEMBL1205426 | 0.80 | CXCR4 (0.71) | CXCR4DRD4MEN1KMT2A | |
| SCHEMBL14619885 | 0.80 | CXCR4 (0.73) | CXCR4TSHRDRD4MEN1KMT2A | |
| SCHEMBL12894196 | 0.79 | CXCR4 (0.78) | CXCR4DRD4MEN1KMT2A | |
| SCHEMBL1637430 | 0.79 | CXCR4 (0.63) | CXCR4TSHRMEN1KMT2AACHE | |
| SCHEMBL1637248 | 0.77 | CXCR4 (0.67) | CXCR4MEN1KMT2AMAOBACHE | |
| SCHEMBL1205955 | 0.77 | CXCR4 (0.92) | CXCR4TSHRDRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | claimed |
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | CXCR4 86/4885TSHR 1111/4885DRD4 834/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | CXCR4 100/4885TSHR 1353/4885DRD4 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.